- Details
- David VanderWeele elucidates findings from the TALAPRO-2 study, emphasizing the substantial hazard ratio benefits observed in metastatic CRPC patients with HRR mutations, especially those with BRCA1 and 2 mutations, treated with enzalutamide combined with talazoparib. However, he raises questions regarding the true representation of the trial's population and a lack of subsequent PARP inhibitor tr...
|
- Details
- Alicia Morgans converses with Ravi Madan about an ongoing trial involving patients with biochemical recurrence of prostate cancer. The unique trial utilizes Prostate-Specific Membrane Antigen (PSMA) PET imaging to routinely monitor patients and to develop an understanding of the natural history of the disease in the context of recurrent prostate cancer. The goal is to prospectively monitor these p...
|
- Details
- Alicia Morgans hosts Sumit Subudhi to discuss underutilized therapies for metastatic castration-resistant prostate cancer (mCRPC). Dr. Subudhi expounds on the complexities of Sipuleucel-T and Radium-223, highlighting their benefits for maintaining patient quality of life. He clarifies that while these therapies do not reduce prostate-specific antigen (PSA) levels, they slow down cancer growth, exp...
|
- Details
- Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik's presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik explain...
|
- Details
- Alicia Morgans and Daniel Sentana Lledo discuss a groundbreaking analysis on data from the CHAARTED study that examined how quality of life impacts survival in metastatic hormone-sensitive prostate cancer patients. Interestingly, patients with better quality of life scores at three months exhibited longer survival times. However, the role of docetaxel (a chemotherapeutic) treatment in this finding...
|
- Details
- Alicia Morgans hosts Tian Zhang to present an update from her presentation on the STARTAR trial, focusing on treatment intensification for high-risk prostate cancer with biochemical recurrence. STARTAR builds on an earlier trial, STREAM, by combining hormone deprivation with apalutamide, salvage radiation, and six cycles of docetaxel. The study focused on patients with Gleason 7 with nodal positiv...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
- Details
- In a conversation between Alicia Morgans and Atish Choudhury, they discuss a study called A-DREAM that is examining the right balance of treatment duration for patients with metastatic prostate cancer. They note that androgen deprivation therapy (ADT) works well for many patients, but it can also lead to complications such as weight gain, muscle loss, and cardiovascular issues over time. To combat...
|
- Details
- In a conversation with Alicia Morgans, Stephen Freedland discusses a study he presented that analyzes Veterans Affairs’ data on men who had received either surgery or radiation therapy for prostate cancer and later developed a biochemical recurrence. The focus is on the 'doubling time' of PSA, a significant prognostic factor. According to the study, the majority of patients with a doubling time of...
|
- Details
- In a conversation between Alicia Morgans and David Olmos, they discussed the exciting findings from Olmos' presentation focusing on prostate cancer patients with BRCA mutations. Dr. Olmos highlighted that BRCA1 and BRCA2 mutation patients, regardless of germline or somatic origin, generally have worse outcomes compared to other patients. The CAPTURE study he spearheaded, which involved multiple co...
|
